In CML, increased levels of MDSC, which originate from the malignant BCR-ABL1 clone, are also observed, and these MDSC subsequently reduce following highly efficacious TKI therapy (12, 13). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.